The oncogenic roles of 27‑hydroxycholesterol in glioblastoma

Liu,Lu; Li,Mei‑Yuan; Xing,Yu; Wang,Xiao‑Yun; Wang,Yong

doi:10.3892/ol.2019.10690

The oncogenic roles of 27‑hydroxycholesterol in glioblastoma

Authors:
- Lu Liu
- Mei‑Yuan Li
- Yu Xing
- Xiao‑Yun Wang
- Yong Wang
View Affiliations

Affiliations: Department of Neurology 4, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Internal 11, Infectious Disease Hospital of Heilongjiang Province, Harbin, Heilongjiang 150500, P.R. China, Department of Neurology, Heilongjiang Agricultural Reclamation Bureau General Hospital, Harbin, Heilongjiang 150088, P.R. China
Published online on: July 31, 2019 https://doi.org/10.3892/ol.2019.10690
Pages: 3623-3629
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma is the most frequent primary malignant brain tumor in adults. Oxysterols are oxidation products of cholesterol generated by enzymatic reactions. 27‑hydroxycholesterol (27‑HC), an oxysterol, is an abundant metabolite of cholesterol. 27‑HC significantly accelerates mammary cancer growth, proliferation and progression in experimental models. However, to the best of our knowledge, the effect of 27‑HC on glioblastoma has not been studied. Therefore, the present study aimed to determine the exact role of 27‑HC in glioblastoma. The present study demonstrated that 27‑HC promoted proliferation, epithelial to mesenchymal transition, colony formation, migration and invasion of U251 and U118 MG glioblastoma cells. Treatment with 27‑HC was also associated with an increase in the formation of glioblastoma‑initiating cells in U251 and U118 MG cell lines. Additionally, it was observed that high levels of 27‑HC in glioblastoma tissues were associated with poor outcome in patients. In conclusion, 27‑HC, a primary metabolite of cholesterol, may serve an important role in the progression of glioblastoma.

View Figures

View References

1	Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol. 30:10–14. 2003. View Article : Google Scholar : PubMed/NCBI
2	Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
3	DeAngelis LM: Brain tumors. N Engl J Med. 344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
4	Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, et al: 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 342:1094–1098. 2013. View Article : Google Scholar : PubMed/NCBI
5	Umetani M and Shaul PW: 27-Hydroxycholesterol: The first identified endogenous SERM. Trends Endocrinol Metab. 22:130–135. 2011. View Article : Google Scholar : PubMed/NCBI
6	Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW and Mangelsdorf DJ: 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 13:1185–1192. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, et al: 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 5:637–645. 2013. View Article : Google Scholar : PubMed/NCBI
8	Vini R, Juberiya AM and Sreeja S: Evidence of pomegranate methanolic extract in antagonizing the endogenous SERM, 27-hydroxycholesterol. IUBMB Life. 68:116–121. 2016. View Article : Google Scholar : PubMed/NCBI
9	Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, et al: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 61:1122–1128. 2001.PubMed/NCBI
10	Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, et al: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 93:1246–1256. 2001. View Article : Google Scholar : PubMed/NCBI
11	Shaw E, Seiferheld W, Scott C, Coughlin C, Leibel L, Curran W and Mehta M: Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients. Int J Radiat Oncol Biol Phys. 57:S135–S136. 2003. View Article : Google Scholar
12	Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, Fu Z and You Y: miR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 1312:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
13	Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942. 2014. View Article : Google Scholar : PubMed/NCBI
14	Li G, Wang R, Gao J, Deng K, Wei J and Wei Y: RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells. Mol Cell Biochem. 350:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al: PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 108(pii): djv3032015.PubMed/NCBI
16	Andersson MK, Afshari MK, Andrén Y, Wick MJ and Stenman G: Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling. J Natl Cancer Inst. 1092017.
17	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
18	Lu DL, Sookthai D, Le Cornet C, Katzke VA, Johnson TS, Kaaks R and Fortner RT: Reproducibility of serum oxysterols and lanosterol among postmenopausal women: Results from EPIC-Heidelberg. Clin Biochem. 52:117–122. 2018. View Article : Google Scholar : PubMed/NCBI
19	Rosner B: Fundamentals of Biostatistics. Nelson Education. (Canada). 286–298. 2015.
20	Metz CE: Basic principles of ROC analysis. Semin Nucl Med. 8:283–298. 1978. View Article : Google Scholar : PubMed/NCBI
21	Zweig MH and Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem. 39:561–577. 1993.PubMed/NCBI
22	Sherry MM, Reeves A, Wu JK and Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem cells. 27:2383–2392. 2009. View Article : Google Scholar : PubMed/NCBI
23	Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP: CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ye X and Weinberg RA: Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kahlert U, Nikkhah G and Maciaczyk J: Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 331:131–138. 2013. View Article : Google Scholar : PubMed/NCBI
26	Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M and Betticher DC: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
27	Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, et al: The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 119:3626–3636. 2009. View Article : Google Scholar : PubMed/NCBI
28	Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
29	Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med. 5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
30	Elsaba TM, Martinez-Pomares L, Robins AR, Crook S, Seth R, Jackson D, McCart A, Silver AR, Tomlinson IP and Ilyas M: The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One. 5:e107142010. View Article : Google Scholar : PubMed/NCBI
31	Lu C and Shervington A: Chemoresistance in gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
32	Bredel M: Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 35:161–204. 2001. View Article : Google Scholar : PubMed/NCBI
33	Bronger H, König J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D and Nies AT: ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res. 65:11419–11428. 2005. View Article : Google Scholar : PubMed/NCBI
34	Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, et al: Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 69:1507–1518. 2012. View Article : Google Scholar : PubMed/NCBI
35	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR and Freshney RI: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
36	Cemeus C, Zhao TT, Barrett GM, Lorimer IA and Dimitroulakos J: Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol. 90:9–17. 2008. View Article : Google Scholar : PubMed/NCBI